| Abstrakt: |
Researchers from Zhengzhou University in China have developed a new method to target and degrade a glycoprotein called LRG1, which is associated with renal fibrosis. The researchers used a peptide to recruit LRG1 and a drug called lenalidomide to engage an E3 ubiquitin ligase, resulting in the degradation of LRG1. In both in vitro and in vivo experiments, the degradation of LRG1 effectively inhibited the TGF-b-Smad3 signaling pathway and reduced the secretion of fibrosis-associated proteins, thereby attenuating the progression of renal fibrosis. This study highlights the potential of this targeted intervention as a therapeutic candidate for renal fibrosis. [Extracted from the article] |
